Assignee
THRESHOLD PHARMACEUTICALS INC
US·11 granted patents·23 pending applications·265 citations·filing 2002–2017
Top patents by PatentIndex Score
34 records- 0197US6979675B2Treatment of cancer with 2-deoxyglucoseTHRESHOLD PHARMACEUTICALS INC·Filed 2004·Granted Dec 27, 2005·119 cites·17 claims
- 0295US6989140B2Methods for cancer imagingTHRESHOLD PHARMACEUTICALS INC·Filed 2002·Granted Jan 24, 2006·55 cites·17 claims
- 0391US7001888B2Compositions and methods for treating cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2003·Granted Feb 21, 2006·40 cites·8 claims
- 0489US8003625B2Phosphoramidate alkylator prodrugsTHRESHOLD PHARMACEUTICALS INC·Filed 2006·Granted Aug 23, 2011·12 cites·20 claims
- 0583US7560230B2Method for determining susceptibility of tumor to treatment with anti-neoplastic agentTHRESHOLD PHARMACEUTICALS INC·Filed 2004·Granted Jul 14, 2009·11 cites·17 claims
- 0679US7550496B2Compositions and methods for treating cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2004·Granted Jun 23, 2009·13 cites·18 claims
- 0777US8664204B2Phosphoramidate alkylator prodrugsTHRESHOLD PHARMACEUTICALS INC·Filed 2013·Granted Mar 4, 2014·2 cites·9 claims
- 0877US6989400B2Treatment of benign prostatic hyperplasiaTHRESHOLD PHARMACEUTICALS INC·Filed 2004·Granted Jan 24, 2006·9 cites·24 claims
- 0976US9205098B2Anti-cancer therapiesTHRESHOLD PHARMACEUTICALS INC·Filed 2012·Granted Dec 8, 2015·2 cites·6 claims
- 1073US9226932B2Phosphoramidate alkylator prodrugsTHRESHOLD PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·1 cites·13 claims
- 1165US9254299B2Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2012·Granted Feb 9, 2016·1 cites·13 claims
- 1264US2005271723A1Dosage forms for treatment of benign prostatic hyperplasiaTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1364US2005272795A1Prevention and treatment of benign prostatic hyperplasiaTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1459US2005245462A1Treatment of cancer with 2-deoxyglucoseTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1558US2006142207A1Compositions and methods for treating cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1657US2015272973A1Treatment of Cancer with Glufosfamide in Patients Not Receiving Insulin TherapyTHRESHOLD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1754US2006172953A1Treatment of benign prostatic hyperplasia using energolytic agentsTHRESHOLD PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 1853US2011182909A1Glufosfamide combination therapyTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1953US2005272796A1Prevention and treatment of benign prostatic hyperplasia using lonidamine and lonidamine analogsTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 2052US2016143929A1Administration of glufosfamide for the treatment of cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2152US2018169064A1Aziridine containing dna alkylating agentsTHRESHOLD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2250US2015258125A1Treatment of cancer using hypoxia activated prodrugsTHRESHOLD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2349US2017157161A1Anti-Cancer TherapiesTHRESHOLD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2445US2009042820A1Tubulin Binding Anti Cancer Agents And Prodrugs ThereofTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 2545US2008214576A1Topoisomerase Inhibitors and ProdrugsTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 2645US2015005262A1Hypoxia activated prodrugs and mtor inhibitors for treating cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 2745US2007015771A1Lonidamine analogsTHRESHOLD PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2845US2007043057A1Lonidamine analogsTHRESHOLD PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2945US2007060534A1Anthracycline analogsTHRESHOLD PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3044US2008132458A1Hypoxia-Activated Anti-Cancer AgentsTHRESHOLD PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 3141US2016296538A1Predictive and response biomarker for th-302 anti-cancer therapyTHRESHOLD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3240US2017232017A1Treatment of cancerTHRESHOLD PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3340US2016158253A1Treatment of pancreatic cancer with a combination of a hypoxia-activated prodrug and a taxaneTHRESHOLD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3439US2015005264A1Predictive biomarker for hypoxia-activated prodrug therapyTHRESHOLD PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when THRESHOLD PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →